# A Rollover Protocol of Dacomitinib For Patients In Japan

> **NCT02382796** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 7 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT02382796
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-10
- **Primary completion:** 2019-05-30
- **Final completion:** 2019-05-30
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2020-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02382796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02382796, "A Rollover Protocol of Dacomitinib For Patients In Japan". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02382796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*